Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kronos Bio Inc
(NQ:
KRON
)
0.9700
+0.0300 (+3.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kronos Bio Inc
< Previous
1
2
3
4
Next >
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
December 18, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
November 27, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
November 20, 2023
Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 13, 2023
Via
Benzinga
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
November 13, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
November 02, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
October 27, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
October 13, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
October 04, 2023
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope
From
Kronos Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 17, 2023
Via
Benzinga
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
August 17, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
August 08, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
June 06, 2023
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences
June 01, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
May 10, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
April 24, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Changes to Board of Directors
April 11, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
April 20, 2023
During Thursday's session, 99 companies made new 52-week lows.
Via
Benzinga
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
March 15, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
February 28, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
5 Most Expensive Health Care Stocks You Should Worry About
January 12, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
January 09, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.